Navigation Links
Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting
Date:3/28/2008

Dr. Bill Poland Will Present on Strategic Use of in Vitro and Literature

Data to Predict Effects of New HIV Therapies

MOUNTAIN VIEW, Calif., March 28 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, has been invited to present at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting at the Orlando World Center Marriott Resort in Orlando, Florida. Dr. Poland will present on April 4, 2008, joining other leading experts from the pharmaceutical industry and academia in a symposium focused on applications of pharmacokinetic/pharmacodynamic (PK/PD) and disease modeling in HIV.

The symposium will provide a forum for scientific discussion and collaborative exchange on model-based approaches to describe and predict drug effects in the treatment of HIV, and will include specific case examples where drug-disease modeling have optimized the clinical development of new anti-HIV drugs. Dr. Poland's presentation, entitled "Using in Vitro and Literature Data to Predict Effects of New Anti-Retrovirals", will describe how PK/PD-viral dynamics models developed using preclinical data and literature data on existing HIV treatments can inform dose-response predictions for new anti-retroviral agents.

In addition to Dr. Poland's presentation, Pharsight scientists have contributed to two separate ASCPT poster presentations that describe model-based approaches to support development decision-making and clinical trial design for drug candidates in oncology and obesity. Further information can be found at http://www.ascpt.org.

"Integrating literature information to permit objective comparisons of drug effects and time course of disease is a critical knowledge management strategy in model-based drug development," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "Model-based approaches continue to show value for enhancing the understanding of complicated diseases in quantitative terms, and for improving the confidence of drug development decisions. Pharsight is pleased to present at this prestigious HIV symposium and to participate at ASCPT, where we look forward to sharing our experience with industry colleagues and interacting with fellow practitioners of modeling and simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
2. Women Invited to Join New Health Registry to Advance Research
3. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
6. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
7. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
8. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
9. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Genzyme Announces Presentation of New Positive Data on Carticel(R)
11. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. ... a federal institution supporting research in Germany ... and patient treatments at the University Clinic Heidelberg as ... The MRIdian Linac program will be headed by ... also heads radiation oncology at the German Cancer Research ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... sugar-free alternative VW+ 002. The drinks have been produced in collaboration with Zlatan ... perform during your workout. , After a successful launch in Sweden last year, ...
(Date:1/20/2017)... ... 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went ... creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age ... at 19 years of age, he joined the Navy and got married right out of ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children and adults ... and achievable answer. “The Land of More and More” is the creation of published ... Indiana where he works with the children’s ministry department. , Michael says that ...
Breaking Medicine News(10 mins):